Download PDF

1. Company Snapshot

1.a. Company Description

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.


The company was formerly known as Coronado Dermatology, Inc.and changed its name to Journey Medical Corporation.Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Show Full description

1.b. Last Insights on DERM

Journey Medical Corporation's recent struggles are attributed to current financial challenges and the need for additional funding. Despite the promising launch of Emrosi, a new formulation of minocycline for rosacea, the company's financial situation remains a concern. The success of Emrosi, which has shown superior efficacy over Oracea in Phase III trials, is crucial for the company's future, but dermatologists' acceptance and PBM positioning are key factors that will impact its commercial success. The upcoming conference call on February 5, 2025, will provide insight into the company's commercial launch plan for Emrosi.

1.c. Company Highlights

2. Journey Medical Surges with Emrosi, Eyes Breakthrough 2026

Journey Medical’s 2025 earnings marked a milestone: net product revenue rose 11% to $61.9 million, while gross margin improved by 3.5 percentage points, reflecting tighter cost control and better pricing power. Adjusted EBITDA turned positive at $2.9 million, and the company reported a GAAP net loss of $11.4 million, translating to an EPS of –$0.04 versus analysts’ –$0.06 expectation (Claude Maraoui). With $24 million in cash and a net debt/EBITDA of 6.89, the firm’s valuation sits at a P/E of –11.08 and a P/S of 2.05, underscoring upside potential if margins continue to climb.

Publication Date: Apr -13

📋 Highlights
  • Emrosi Launch Success: Generated $14.7M net sales in first 3 quarters, with 53,000 prescriptions written by 3,500+ prescribers.
  • Revenue & Margin Growth: Total net product revenue grew 11% YoY, gross margin improved 3.5pp, and adjusted EBITDA turned positive in Q4 2025.
  • Strong Cash Position: Held $24M in cash, with $2.9M adjusted EBITDA for 2025 and plans to remain EBITDA-positive in 2026.
  • GPO Expansion & Reimbursement: Secured 2/3 top GPO contracts, expecting improved reimbursement and gross-to-net dynamics in 2026.
  • Product Pipeline: Plans to launch 1-2 derm products in 2026 and announce 3 new Emrosi studies, driving portfolio growth.

Emrosi Commercial Performance

Since its April 2025 launch, Emrosi has delivered $14.7 million in net sales across three quarters, supported by 53,000 prescriptions and a 50% sequential growth in Q4. The product now enjoys coverage from 3,500 unique dermatology prescribers, indicating strong market penetration. Despite a dip in revenue per script to $180 in Q4 from $380 in Q2, the decline is attributed to reimbursement dynamics and the co‑pay assistance program, rather than a pricing erosion (Scott Henry).

Gross‑to‑Net Dynamics

Journey anticipates a systematic improvement in gross‑to‑net ratios as two of three top GPOs onboarded in 2026. The company projects a run‑rate of 126,000 prescriptions in Q4, with expectations to surpass this figure as reimbursement strengthens. This shift should lift gross margin further, as the company’s gross‑to‑net is already on track and inventory levels remain within industry norms (Claude Maraoui).

Financial Health & Cash Position

With a robust $24 million cash reserve and a manageable accounts receivable profile—despite a Q4 uptick that is largely a timing issue—the firm is well‑positioned to fund its growth agenda. Joseph Benesch noted that improved gross margins will emerge as Emrosi and the upcoming QBREXZA become larger revenue contributors, while period costs are being optimized to reduce operating expenses.

Future Product Pipeline

Journey plans to introduce 1–2 niche dermatology products in 2026, with a second‑half launch slated for Q3. These additions aim to diversify the revenue base and accelerate top‑line growth, potentially driving a 63.2% revenue increase next year. The company also expects to release up to three new journal publications on Emrosi, bolstering clinical credibility.

Analyst Outlook & Valuation

Analysts project a 63.2% revenue jump in 2026, contingent on the GPO rollout and gross‑to‑net gains. Valuation metrics—particularly the negative P/E and EV/EBITDA—highlight a discount relative to peers, suggesting that a sustained margin expansion could unlock significant shareholder value. The company’s focus on margin optimization, coupled with a strong product pipeline, positions it for a breakthrough year if reimbursement dynamics continue to improve.

3. NewsRoom

Card image cap

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Apr -16

Source: prnewswire.com

Card image cap

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Apr -14

Source: globenewswire.com

Card image cap

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Apr -09

Source: prnewswire.com

Card image cap

Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr -02

Source: globenewswire.com

Card image cap

Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts

Apr -01

Source: defenseworld.net

Card image cap

Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Mar -26

Source: zacks.com

Card image cap

Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript

Mar -26

Source: seekingalpha.com

Card image cap

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar -25

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.50%)

6. Segments

Products for the Treatment of Dermatological Conditions.

Expected Growth: 5.5%

Growing demand for dermatological treatments, increasing awareness of skin health, and advancements in topical formulations drive growth in the market for Journey Medical Corporation's products, which offer effective solutions for acne, rosacea, and skin aging.

7. Detailed Products

Luzu

A topical cream used to treat inflammatory and pruritic manifestations of atopic dermatitis in patients 3 months and older.

Exelderm

A topical cream used to treat fungal infections such as athlete's foot, jock itch, and ringworm.

Nexodyn

A topical gel used to treat acne, including blackheads, whiteheads, and inflamed pimples.

QBREXZA

A topical cloth used to treat primary axillary hyperhidrosis (excessive sweating) in adults and children 9 years and older.

Zilxi

A topical cream used to treat inflammatory lesions of rosacea in adults.

8. Journey Medical Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Journey Medical Corporation's products are moderately susceptible to substitutes, as there are alternative treatments and products available in the market.

Bargaining Power Of Customers

Journey Medical Corporation's customers have limited bargaining power due to the specialized nature of its products and the lack of alternative suppliers.

Bargaining Power Of Suppliers

Journey Medical Corporation's suppliers have moderate bargaining power due to the availability of alternative suppliers and the company's dependence on a few key suppliers.

Threat Of New Entrants

The threat of new entrants is high in the pharmaceutical industry, as new companies can enter the market with innovative products and technologies.

Intensity Of Rivalry

The intensity of rivalry in the pharmaceutical industry is high, with many established companies competing for market share and new entrants disrupting the market.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 46.55%
Debt Cost 7.86%
Equity Weight 53.45%
Equity Cost 7.86%
WACC 7.86%
Leverage 87.08%

11. Quality Control: Journey Medical Corporation passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Supernus Pharmaceuticals

A-Score: 5.9/10

Value: 9.1

Growth: 6.0

Quality: 5.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Aytu BioPharma

A-Score: 4.8/10

Value: 9.4

Growth: 4.7

Quality: 4.2

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Amphastar Pharmaceuticals

A-Score: 4.6/10

Value: 6.7

Growth: 8.9

Quality: 6.3

Yield: 0.0

Momentum: 1.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Journey Medical

A-Score: 4.2/10

Value: 6.6

Growth: 3.3

Quality: 4.2

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Alimera Sciences

A-Score: 3.8/10

Value: 7.3

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
PetIQ

A-Score: 3.7/10

Value: 3.7

Growth: 7.7

Quality: 3.1

Yield: 0.0

Momentum: 6.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.39$

Current Price

5.39$

Potential

-0.00%

Expected Cash-Flows